June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Real-world outcomes with ranibizumab 0.5 mg treatment in French patients with visual impairment due to diabetic macular edema: 12-month results from the 36-month BOREAL-DME study
Author Affiliations & Notes
  • Catherine P Creuzot Garcher
    Ophthalmology, University Hospital, Dijon, France
  • Pascale Massin
    Ophthalmology, Hopital Lariboisière, Paris, France
  • Laurent KODJIKIAN
    Ophthalmology, Hopital de la Croix Rousse, Lyon, France
  • Jean-Francois Girmens
    Ophthalmology, CHNO des Quinze-Vingts, Paris, France
  • Cecile DelCourt
    Inserm U1219-Bordeaux Population Health Research Center, University of Bordeaux, Bordeaux, France
  • Frank Fajnkuchen
    Ophthalmology, Hôpital Avicenne, Bobigny, Bobigny, France
  • Agnès Glacet
    Ophthalmology, Centre Hospitalier Intercommunal de Créteil, Créteil, France
  • Pierre-Jean Guillausseau
    Internal Medicine, Hopital Lariboisière, Paris, France
  • Audrey Derveloy
    Novartis Pharma SAS, Rueil-Malmaison, Malmaison, France
  • Laetitia FINZI
    Novartis Pharma SAS, Rueil-Malmaison, Malmaison, France
  • Patrick Blin
    Medical Pharmacology Dept., Medical Pharmacology department CIC Bordeaux CIC1401, Bordeaux, Bordeaux, France
  • BPE Team
    Medical Pharmacology Dept., Medical Pharmacology department CIC Bordeaux CIC1401, Bordeaux, Bordeaux, France
  • Footnotes
    Commercial Relationships   Catherine Creuzot Garcher, Alcon (C), Allergan (C), Bausch & Lomb (C), Bayer (C), Novartis (C); Pascale Massin, Allergan (C), Bayer (C), Novartis (C), Ophthotech (C), Roche (C), Topcon (C); Laurent KODJIKIAN, Alcon (C), Allergan (C), Bayer (C), Novartis (C), Thea (C); Jean-Francois Girmens, Allergan (C), Bayer (C), Novartis (C); Cecile DelCourt, Allergan (C), Bausch & Lomb (C), Novartis (C), Roche (C), Thea (C); Frank Fajnkuchen, Allergan (C), Bayer (C), Novartis (C); Agnès Glacet, Allergan (C), Bayer (C), Novartis (C); Pierre-Jean Guillausseau, Astra Zeneca (C), BMS (C), Novartis (C), Sanofi (C), Servier (C); Audrey Derveloy, Novartis Pharma SAS, Rueil-Malmaison (E); Laetitia FINZI, Novartis Pharma SAS, Rueil-Malmaison (E); Patrick Blin, Novartis (F); BPE Team, Novartis Pharma SAS (F)
  • Footnotes
    Support  Novartis Pharma SAS
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 1915. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Catherine P Creuzot Garcher, Pascale Massin, Laurent KODJIKIAN, Jean-Francois Girmens, Cecile DelCourt, Frank Fajnkuchen, Agnès Glacet, Pierre-Jean Guillausseau, Audrey Derveloy, Laetitia FINZI, Patrick Blin, BPE Team; Real-world outcomes with ranibizumab 0.5 mg treatment in French patients with visual impairment due to diabetic macular edema: 12-month results from the 36-month BOREAL-DME study. Invest. Ophthalmol. Vis. Sci. 2017;58(8):1915.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To assess the effectiveness and safety of ranibizumab 0.5 mg in French patients with visual impairment due to diabetic macular edema (DME) from the 36-month BOREAL-DME study. Here, we present 12-month follow-up results from this study.

Methods : This is a mandatory, noninterventional, multicenter, post-authorization, observational cohort study conducted in France. Patients with Type 1 or 2 diabetes aged ≥18 years who had a reduction in BCVA due to DME and for whom ranibizumab therapy was initiated by the treating physician were included in the study. The primary endpoint was the mean change in best-corrected visual acuity (BCVA) at Month 12 compared with baseline. Key secondary endpoints were the proportion of patients with BCVA gain or loss of ≥5, ≥10, and ≥15 letters at Month 12, mean change in central subfield thickness (CSFT) at Month 12, treatment exposure to ranibizumab, and safety up to Month 12.

Results : Of the 344 enrolled patients, 242 patients (83.4%) completed the 12-month follow-up. At baseline, the mean (standard deviation [SD]) age of the patients was 66.1 (11.0) years and 56.6% were male. The mean duration of DME was more than 6 months in 43.8% of patients, mean HbA1c was 7.6% (1.4), and 66.5% of patients presented with bilateral DME. The mean baseline BCVA and CSFT were 59.2 letters [95% confidence interval (CI): 57.0, 61.0] and 457.0 μm [95%CI: 438, 476], respectively. At Month 12, the mean change in BCVA from baseline was 7.4 letters [95%CI: 5.4, 9.4], with 36.8% of patients with BCVA >70 letters vs 13.2% at baseline. The proportion of patients with BCVA gain of ≥5, ≥10, and ≥15 letters and those with BCVA loss of ≥5, ≥10, and ≥15 letters at Month 12 are displayed in Figure 1. The mean change in CSFT at Month 12 from baseline was −129.0 μm [95%CI: −146.0, −103.0]. The mean (SD) number of ranibizumab injections in the study eye was 5.1 (2.3). No new safety findings were identified.

Conclusions : Ranibizumab 0.5 mg treatment improves visual acuity in patients with visual impairment due to DMA in routine clinical practice with fewer injections than reported in clinical trials. The safety profile of ranibizumab was consistent with previously reported DME studies.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×